Wells Fargo
GANX icon

Wells Fargo’s Gain Therapeutics GANX Stock Holding History

Wells Fargo’s Portfolio GANX Stock Details GANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.1K Sell
9,400
-1,650
-15% -$3.04K ﹤0.01% 5936
2026
Q1 		$21.4K Buy
11,050
+8,400
+317% +$18.3K ﹤0.01% 5747
2025
Q4 		$8.53K Hold
2,650
– – ﹤0.01% 5983
2025
Q3 		$4.69K Hold
2,650
– – ﹤0.01% 6082
2025
Q2 		$4.77K Hold
2,650
– – ﹤0.01% 6099
2025
Q1 		$5.06K Hold
2,650
– – ﹤0.01% 6027
2024
Q4 		$5.72K Hold
2,650
– – ﹤0.01% 6040
2024
Q3 		$4.72K Hold
2,650
– – ﹤0.01% 5924
2024
Q2 		$3.39K Sell
2,650
-1,106
-29% -$2.87K ﹤0.01% 5935
2024
Q1 		$14.2K Buy
3,756
+29
+0.8% +$120 ﹤0.01% 5661
2023
Q4 		$12.2K Buy
3,727
+4
+0.1% +$11 ﹤0.01% 5783
2023
Q3 		$12.2K Buy
3,723
+5
+0.1% +$19 ﹤0.01% 5751
2023
Q2 		$16.7K Buy
3,718
+5
+0.1% +$24 ﹤0.01% 5791
2023
Q1 		$17.9K Buy
3,713
+1
+0% +$4 ﹤0.01% 5677
2022
Q4 		$11.6K Buy
3,712
+1,001
+37% +$3.13K ﹤0.01% 5490
2022
Q3 		$9K Buy
2,711
+36
+1% +$135 ﹤0.01% 5721
2022
Q2 		$10K Buy
2,675
+2
+0.1% +$7 ﹤0.01% 5747
2022
Q1 		$11K Buy
2,673
+2,650
+11,522% +$11.1K ﹤0.01% 6233
2021
Q4 		$0 Hold
23
– – ﹤0.01% 7420
2021
Q3 		$0 Sell
23
-1
-4% -$8 ﹤0.01% 7154
2021
Q2 		$0 Buy
+24
New +$271 ﹤0.01% 7073

Other funds holding GANX

Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PCM
Potomac Capital Management New York $147M AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Wells Fargo's GANX Position: Q2 2026 in Review

Wells Fargo reduced its Gain Therapeutics (GANX) stake by 15% in Q2 2026, selling an estimated $3.04K and leaving 9,400 shares worth $19.1K. The position accounts for ﹤0.01% of the portfolio, ranked #5936.

Wells Fargo first reported a position in GANX in Q2 2021 and has held it in 21 quarters since. The position peaked at $21.4K in Q1 2026. 50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

  • Wells Fargo held 9,400 shares of Gain Therapeutics worth $19.1K as of Q2 2026.
  • Wells Fargo sold 1,650 Gain Therapeutics shares in Q2 2026, an estimated $3.04K.
  • Gain Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #5936 holding.
  • Wells Fargo first reported a position in Gain Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • Wells Fargo's Gain Therapeutics position peaked at $21.4K in Q1 2026.
  • 50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.